English  |  正體中文  |  简体中文  |  Total items :2854037  
Visitors :  45317328    Online Users :  975
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

Jump to a point in the index:
Or type in a year:
Show Most Recent First Ordering With Oldest First

Showing items 2260916-2260925 of 2346973  (234698 Page(s) Totally)
<< < 226087 226088 226089 226090 226091 226092 226093 226094 226095 226096 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-02-21T02:04:31Z APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy Lau G.; Yu M.-L.; Wong G.; Thompson A.; Ghazinian H.; Hou J.-L.; Piratvisuth T.; Jia J.-D.; Mizokami M.; Cheng G.; Chen G.-F.; Liu Z.-W.; Baatarkhuu O.; ANN-LII CHENG; Ng W.L.; Lau P.; Mok T.; Chang J.-M.; Hamid S.; Dokmeci A.K.; Gani R.A.; Payawal D.A.; Chow P.; Park J.-W.; Strasser S.I.; Mohamed R.; Win K.M.; Tawesak T.; Sarin S.K.; Omata M.
臺大學術典藏 2022-02-21T02:04:32Z Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; ANN-LII CHENG; Lu Y.-S.
臺大學術典藏 2022-02-21T02:04:32Z Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I.
臺大學術典藏 2022-02-21T02:04:32Z Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J.
臺大學術典藏 2022-02-21T02:04:33Z Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG; Hsu C.; Liang P.-C.; Shih T.T.-F.
臺大學術典藏 2022-02-21T02:04:33Z Evolution of systemic treatment for advanced hepatocellular carcinoma Wu T.-C.; Shen Y.-C.; ANN-LII CHENG
臺大學術典藏 2022-02-21T02:04:33Z Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort Chen K.-H.; Lin L.-I.; Yuan C.-T.; Tseng L.-H.; Chao Y.-L.; Liang Y.-H.; Liang J.-T.; Lin B.-R.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏 2022-02-21T02:04:34Z Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; ANN-LII CHENG; Lin Z.-Z.
臺大學術典藏 2022-02-21T02:04:34Z Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M.
臺大學術典藏 2022-02-21T02:04:35Z Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C.

Showing items 2260916-2260925 of 2346973  (234698 Page(s) Totally)
<< < 226087 226088 226089 226090 226091 226092 226093 226094 226095 226096 > >>
View [10|25|50] records per page